Catalyst Biosciences (US based, NASDAQ: CBIO)
Catalyst was looking to sell several non-core assets after its merger with Targacept. Assets targeted multiple therapeutic areas and Catalyst was looking to leverage Extera’s broad expertise and access to major biopharma players as well as non-traditional buyers.
Extera repositioned the assets, prepared the outreach materials, identify potential buyers, presented the assets and negotiated transactions on behalf of Catalyst. In addition to obvious potential interested parties, and given the unique nature and stage of development of the assets, Extera also aggressively outreached to small cap companies, private companies and venture investors. Extera facilitated asset sales deal with Attenua and additional two undisclosed buyers.
$200m structured Catalyst’s asset sales agreements.